Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®
April 21 2022 - 12:20PM
Biofrontera Inc. (Nasdaq:
BFRI), a biopharmaceutical company specializing in the
commercialization of dermatological products, announced today the
launch of new and updated websites for its two products, Ameluz®
and Xepi®. Now each brand has two websites in one featuring a
patient-focused and a healthcare professional (HCP)-focused website
with appropriate content for both audiences.
To view the new websites, please visit
www.ameluz.com for Ameluz® or www.xepicream.com for Xepi®.
“A full team of Biofrontera employees provided
multidisciplinary input for the construction of our new
brand-specific websites, with fresh content and compelling
graphics. Expanding our digital footprint with a patient-focused
landing page is a first for Ameluz® and a significant upgrade for
Xepi® that provides helpful tools and guidance for patients and
prescribers to improve access, knowledge and reimbursement. The
launch of these websites, which as part of broader campaigns were
developed and tested with external audiences, marks an important
step in our initiative to enhance medical affairs and build brand
awareness. Educating the industry on the importance of field
therapy and the efficacy of our products is a critical component of
our market expansion and commercial strategy that we believe will
increase utilization of photodynamic therapy (PDT),” stated Erica
Monaco, Chief Executive Officer of Biofrontera Inc.
The new websites feature designs, content and
tools that help improve access for patients and highlight product
benefits for prescribers. The patient-focused website for Xepi®
provides easy-to-follow explanations for accessing Xepi® through
special pharmacies using the available co-pay program. The website
for Ameluz® represents the first-ever patient-focused website for
the drug and provides patients with a comprehensive overview of
actinic keratosis (AK) and its treatment with Ameluz®, including
prescribing information and a downloadable brochure.
For healthcare professionals, the Xepi® website
features an access map and sample request form. The Ameluz®
HCP-focused website showcases the benefits of PDT field treatment
for AK, the first commercial preview of the RhodoLED® XL
illumination lamp and physician support information related to
access and reimbursement.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on PDT and topical antibiotics. The
Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as
impetigo, a bacterial skin infection. For more information, visit
https://www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the expected trading commencement and
closing dates. We have based these forward-looking statements on
our current expectations and projections about future events,
nevertheless, actual results or events could differ materially from
the plans, intentions and expectations disclosed in, or implied by,
the forward-looking statements we make. These risks and
uncertainties, many of which are beyond our control, including, but
not limited to, the impact of extraordinary external events, such
as the current COVID-19 pandemic; any changes in the Company’s
relationship with the Licensor; the Company’s ability to achieve
and sustain profitability; whether the current global disruptions
in supply chains will impact the Company’s ability to obtain and
distribute its licensed products; changes in the practices of
healthcare providers, including any changes to the coverage,
reimbursement and pricing for procedures using the Company’s
licensed products; the uncertainties inherent in the initiation and
conduct of clinical trials; availability and timing of data from
clinical trials; whether results of earlier clinical trials or
trials of Ameluz® in combination with BF-RhodoLED® in different
disease indications or product applications will be indicative of
the results of ongoing or future trials; uncertainties associated
with regulatory review of clinical trials and applications for
marketing approvals; whether the market opportunity for Ameluz® in
combination with BF-RhodoLED® is consistent with the Company’s
expectations; whether the Company will be able to successfully
continue its transition to a public company operating independently
of Biofrontera AG; the Company’s ability to retain and hire key
personnel; the sufficiency of cash resources and need for
additional financing and other factors that may be disclosed in the
Company’s filings with the SEC, which can be obtained on the SEC
website at www.sec.gov. Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date on which they are made and reflect management's current
estimates, projections, expectations and beliefs. The company does
not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in
this press release except as required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Oct 2023 to Oct 2024